

No.: 398.../2026/CBTT-NTF

Nghe An, date 17 month 9 year 2026

EXTRAORDINARY INFORMATION DISCLOSURE

To: - State Securities Commission
- Hanoi Stock Exchange

I. Disclosing Organization

- Organization Name: Nghe An Pharmaceutical Medical Material and Equipment Joint Stock Company ("the Company")
- Stock Code: NTF
- Head Office Address: No. 16, Nguyen Thi Minh Khai, Thanh Vinh Ward, Nghe An Province
- Phone: 0238 384 1642 Fax: 038 3848720
- Email: dna@dnapharma.com.vn

II. Contents of Information Disclosure

Nghe An Pharmaceutical Medical Material and Equipment Joint Stock Company announces the report on the progress of the use of capital/proceeds from the Company's offering.

III. This information was published on the website of Nghe An Pharmaceutical Medical Material and Equipment Joint Stock Company on September 17, 2026 at the following link:
<https://dnapharma.com.vn/quan-he-co-dong>

We hereby commit that the information published above is true and accurate and we assume full legal responsibility for the content of the published information./.

Attached documents:

- Report On The Progress Of Use Of Capital/Proceeds Raised From The Offering.

**AUTHORIZED PERSON FOR INFORMATION
DISCLOSURE**



Nguyễn Đình Thanh

**NGHE AN PHARMACEUTICAL
MEDICAL MATERIAL AND
EQUIPMENT JOINT - STOCK
COMPANY**

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness



No.: 399/2026/BC-DNA

Nghe An, date 17 month 09 year 2026

**REPORT ON THE PROGRESS OF USE OF CAPITAL/PROCEEDS RAISED FROM
THE OFFERING**

*(Pursuant to the Certificate of offering registration No. 553/GCN-UBCK issued by the
Chairperson of the State Securities Commission on December 26, 2025)*

To: State Securities Commission

I. INTRODUCTION OF THE ISSUING ORGANIZATION

1. Name of the issuing organization (*in full*): Nghe An Pharmaceutical Medical Material And Equipment Joint - Stock Company
2. Head office address: No. 16, Nguyen Thi Minh Khai, Thanh Vinh Ward, Nghe An Province
3. Telephone: 038 3844741 Fax: 038 3848720 Website: <https://dnapharma.com.vn/>
4. Charter capital: 150,000,000,000 dong.
5. Stock code (*if any*): NTF
6. Payment account-opening bank: Southeast Asia Commercial Joint Stock Bank – Nghe An Branch
Account number: 44 00000 1455899
7. Business Registration Certificate No. 2900491298, first issued by the Department of Planning and Investment of Nghe An Province on January 30, 2002, and amended for the 14th time on March 27, 2026.
 - Main business line: Manufacture of pharmaceuticals, medicinal chemical products and medicinal materials (Details: Manufacture of medicines, functional foods, fortified foods, medicinal chemicals, medicinal materials, pharmaceutical raw materials and auxiliary materials, and processing of medicinal materials) – Business line code: 2100 (main).
 - Main products/services: Manufacture of medicines and functional foods; operation of pharmacies and drugstores.
8. Establishment and operation licenses (*if any, as prescribed by specialized laws*):
 - Decision No. 1206/QD-BYT issued by the Ministry of Health on May 16, 2022, regarding the issuance of the Certificate of eligibility for pharmaceutical business to Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (DNA PHARMA);
 - Decision No. 602/QD-QLD issued by the Drug Administration of Vietnam - Ministry of Health on August 15, 2023, regarding the issuance of the certificate of “Good

manufacturing practices for medicinal products and medicinal ingredients” to Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company (DNA PHARMA);

- Certificate of compliance with “Good distribution practices for medicinal products and medicinal ingredients” (GDP) No. 02/08/GDP issued by the Nghe An Department of Health on June 21, 2024.

II. OFFERED SECURITIES

1. Name of securities: Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company
2. Type of securities: Ordinary shares
3. Par value: 10,000 dong
4. Number of securities offered: 9,000,000 shares
5. Total capital/proceeds raised: 90.000.000.000 dong, of which the amount raised for the project *(in case of using capital to implement a project)*: 82,000,000,000 dong.
6. Closing date of the offering: March 11, 2026.

III. PROGRESS OF USE OF CAPITAL/PROCEEDS RAISED FROM THE OFFERING

1. Plan for use of capital:

- 1.1. Plan for use of capital/proceeds raised from the offering:

Pursuant to the Resolution of the 2025 Annual General Meeting of Shareholders adopted on May 29, 2025, and Resolution of the Board of Directors No. 58/2025/NQ-HDQT dated November 27, 2025, approving the detailed plan for use of proceeds raised from the public offering of shares to existing shareholders to increase charter capital:

No.	Plan for use of capital	Expected allocated amount (VND)	Expected disbursement period
I	For construction activities of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park	82,000,000,000	Q4/2025 – Q2/2026
1	Plant 01	14,977,931,196	Q4/2025 – Q2/2026
2	Plant 02	8,367,750,008	Q4/2025 – Q2/2026
3	Plant 03	3,919,069,190	Q4/2025 – Q2/2026
4	Plant 04	3,628,060,694	Q4/2025 – Q2/2026
5	Plant 05	4,744,855,649	Q4/2025 – Q2/2026
6	Office building 05A	15,429,230,592	Q4/2025 – Q2/2026
7	Plant 06	20,073,408,205	Q4/2025 – Q2/2026
8	External auxiliary works	3,762,464,582	Q4/2025 –

No.	Plan for use of capital	Expected allocated amount (VND)	Expected disbursement period
			Q2/2026
9	Ground leveling	516,241,931	Q4/2025 – Q2/2026
10	Traffic infrastructure	6,580,987,953	Q4/2025 – Q2/2026
II	Supplementing working capital to pay for the purchase of raw materials and goods serving production and business activities	8,000,000,000	Q4/2025 – Q2/2026
	Total	90,000,000,000	

1.2. Amended plan for use of capital::

Pursuant to Resolution of the Board of Directors No. 43/2026/NQ-HDQT dated June 11, 2026, approving the amendment to the plan for use of capital approved under the Resolution of the Annual General Meeting of Shareholders dated May 29, 2025, and Resolution of the Board of Directors No. 58/2025/NQ-HDQT dated November 27, 2025, specifically as follows: Deposit 40,000,000,000 dong in savings (in words: Forty billion dong, equivalent to 44.44% of the total proceeds raised from the offering), out of the 82 billion dong expected to be allocated for construction activities of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park (the “Project”), during the period when such funds have not yet been used/are awaiting disbursement for the Project’s construction activities, in order to ensure efficient use of capital.

2. Information on the progress of the issuing organization’s project (*in case of using capital to implement a project*)

- Project progress according to the published plan: As set out in Section 1.1/III above.
- Current project progress: The Project is undergoing final settlement for the bid packages/work items that have been implemented. As final settlement with the contractors has not yet been completed, disbursement for payment has not been made. The Company will make disbursements immediately upon completion of the final settlement documentation with the contractors.

Bid packages/work items that have not yet been implemented are temporarily suspended pending consideration of adjustments to the Project’s design to ensure compliance with international standards for pharmaceutical manufacturing plants.

3. Progress of use of capital/proceeds raised from the offering:

- Progress of use of capital/proceeds raised from the offering/issuance and amendments to the plan for use of capital up to the present:



No.	Plan for use of capital	Planned use under the Resolution of the 2025 Annual General Meeting of Shareholders dated May 29, 2025, and Resolution of the Board of Directors No. 58/2025/NQ-HDQT (VND)	Actual amount of capital used (VND)	Capital utilization date	Note
I	For construction activities of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park	82.000.000.000	40,000,000,000 <i>(Pursuant to Resolution of the Board of Directors No. 43/2026/NQ-HDQT dated June 11, 2026, the Company deposited 40 billion dong in a three-month savings account at Southeast Asia Commercial Joint Stock Bank on June 17, 2026.)</i>	June 17, 2026	40 billion dong has been disbursed for the savings deposit; the remaining 42 billion dong expected to be allocated to the Project has not yet been disbursed because the final settlement with the Contractors has not been completed.
1	Plant 01	14,977,931,196			
2	Plant 02	8,367,750,008			
3	Plant 03	3,919,069,190			
4	Plant 04	3,628,060,694			
5	Plant 05	4,744,855,649			
6	Office building 05A	15,429,230,592			
7	Plant 06	20,073,408,205			
8	External auxiliary works	3,762,464,582			
9	Ground leveling	516,241,931			
10	Traffic infrastructure	6,580,987,953			
II	Supplementing working capital to pay for the purchase of raw materials and goods serving production and business activities	8,000,000,000	-	-	Not disbursed
	Total	90,000,000,000	40,000,000,000		

- Reason for amendment (if any): The Company is considering adjustments to certain work items of the Project and has therefore not continued implementing the Project's construction work items/bid packages;

Regarding the supplementation of working capital, as the Company's demand for purchasing raw materials and goods serving its production and business activities has decreased compared with the plan, the Company has proactively used its own funds to pay the expenses incurred.

4. The report on the progress of use of capital/proceeds raised from the offering/issuance has been disclosed on the Company's website at <https://dnapharma.com.vn/quan-he-co-dong> since 17/09/2026.

Nghe An, date 17 month 09 year 2026
**NGHE AN PHARMACEUTICAL MEDICAL
MATERIAL AND EQUIPMENT JOINT -
STOCK COMPANY
LEGAL REPRESENTATIVE
CHAIRPERSON OF THE BOARD OF
DIRECTORS**

(signed)

Nguyen Van Thang

